Liver Neoplasms × Gynecologic × Clear all
NCT07124000 2026-02-24

DP-04

AstraZeneca

Recruiting
100 enrolled
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

Phase 1/2 Not yet recruiting
60 enrolled
NCT06171945 2025-10-27

AYAConnect

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
63 enrolled
NCT06582849 2025-08-26

EARN

Washington University School of Medicine

Phase NA Completed
33 enrolled
NCT06239194 2025-06-22

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
115 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT06787807 2025-01-22

Proteomic Analysis of Patients Undergoing Bariatric Surgery

Universidade Federal de Pernambuco

Phase NA Not yet recruiting
103 enrolled
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
NCT02333604 2024-04-15

CER

Cancer Support Community, Research and Training Institute, Philadelphia

Recruiting
15,000 enrolled
NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
NCT04670445 2023-10-23

UPLIFT

Massachusetts General Hospital

Phase NA Unknown
210 enrolled
NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

Phase 1/2 Completed
49 enrolled
NCT05886075 2023-06-02

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

Shanghai Yunying Medical Technology

Phase EARLY_PHASE1 Unknown
24 enrolled
NCT03849469 2023-03-30

DUET-4

Xencor, Inc.

Phase 1 Completed
78 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT02315066 2022-04-21

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Pfizer

Phase 1 Completed
174 enrolled 68 charts